What Sanoculis does

Sanoculis Ltd. is an Israeli medical device company founded in 2012 and headquartered in Kiryat Ono, Israel. The company develops proprietary, stent-free, minimally invasive surgical platforms for the treatment of glaucoma: MINT® (Minimally Invasive Nasal Trabeculostomy), which uses a semi-automated mechanical trephination with a 0.14mm cutting edge to create five drainage pathways in the trabecular meshwork, and MIMS® (Minimally Invasive Micro Sclerostomy), a stentless procedure that creates a sclerostomy channel for continuous aqueous drainage. Both platforms are designed for standalone use or in combination with cataract surgery (phacoemulsification), targeting ophthalmologists and glaucoma surgeons in hospitals and eye surgery centers.

The technology stack is mechanical and procedural rather than digital: the MINT® device is positioned on the trabecular meshwork via a gonioscope and operated via a foot pedal, while the MIMS® system includes a touchscreen-controlled surgical console with a handheld cutting tool. MIMS® is CE marked under MDD 93/42/EEC and MINT® is CE marked under MDR 2017/745, both registered trademarks of Sanoculis. Clinical data show 97.2% qualified success at two years for MINT® standalone (FDA definition, N=35/36), 36% IOP reduction with 50% medication reduction at two years, and for MIMS®, 38% IOP reduction and 85% medication reduction at 12 months with zero major intra/post-operative complications (N=120) and a procedure duration of 2:03 ± 0:43 minutes.

Sanoculis generates revenue through hardware sales of MINT® and MIMS® devices to healthcare providers, with distribution executed through exclusive channel partners: Bausch + Lomb holds exclusive European distribution rights for MIMS® (as of the January 2023 Series C round), and Skymed distributes Sanoculis products in Israel. Pricing is quote-based and not publicly disclosed. The company is venture-backed (Series C, January 2023, with Eckuity and Bausch + Lomb as investors), maintains a Medical Advisory Board of globally recognized glaucoma surgeons, and shows operational footprints in Israel, Europe, India, and signals of early US expansion via a VP of Clinical Affairs US.

Name

Sanoculis

Legal name

Sanoculis LTD.

Website

https://sanoculis.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Sanoculis is an Israeli medical device company that develops proprietary stent-free, minimally invasive surgical platforms — MINT® and MIMS® — for the treatment of open-angle glaucoma, sold to ophthalmologists and glaucoma surgeons through exclusive distributors.

Ownership category

akta.pro rank

Headquarters

HQ city

Kiryat Gat

HQ country

Israel

HQ region

Middle East

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Marketing or Sales, Personnel, Operations

Revenue model

1. Medical Device Sales: Sanoculis generates revenue through the sale of its proprietary MINT® and MIMS® surgical devices and related surgical systems. As a medical device company, revenue is derived from hardware/device sales to healthcare providers, hospitals, and eye surgery centers. Distribution is primarily through exclusive channel partners in international markets.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Sanoculis develops and sells two proprietary, stent-free, minimally invasive ophthalmic surgical devices for glaucoma treatment: MINT® (Minimally Invasive Nasal Trabeculostomy) and MIMS® (Minimally Invasive Micro Sclerostomy). Both devices are sold to hospitals, eye surgery centers, and ophthalmologists for standalone use or in combination with cataract surgery, and are CE marked for the European market.

Product overview

Sanoculis is a medical device company specializing in ophthalmic technology with two core stentless, minimally invasive glaucoma treatment products: MINT® (Minimally Invasive Nasal Trabeculostomy), which creates trabecular meshwork drainage pathways via a semi-automated trephination device, and MIMS® (Minimally Invasive Micro Sclerostomy), which creates a sclerostomy channel for IOP reduction. Both devices are designed for standalone use or combination with cataract surgery, offering stent-free alternatives to traditional filtration surgery with lower complication rates.

Differentiator

Problem solved

Functional benefit

Brands

• MINT®: Minimally Invasive Nasal Trabeculostomy - A CE marked device under MDR 2017/745 for glaucoma treatment. Creates five drainage pathways directly within the trabecular meshwork using a mechanical semi-automated trephination with a cutting edge diameter of 0.14mm.
• MIMS®

Products and services

• MINT® (Minimally Invasive Nasal Trabeculostomy) MINT® is a stent-free, minimally invasive ophthalmic surgical device that creates five drainage pathways directly within the trabecular meshwork using a proprietary mechanical semi-automated trephination with a 0.14mm cutting edge diameter. It is intended for ophthalmologists and glaucoma surgeons to lower intraocular pressure in open-angle glaucoma patients, either as a standalone procedure or combined with cataract surgery.
• MIMS® (Minimally Invasive Micro Sclerostomy) MIMS® is a stentless ophthalmic surgical device and system that creates a sclerostomy by inserting a cutting tool into the sclera to remove a small channel of tissue, allowing continuous drainage of fluid to reduce intraocular pressure. The accompanying surgical system features a central control touchscreen and a foot pedal for precise handheld cutting tool movement. It is sold to hospitals and ophthalmologists for standalone glaucoma surgery or combined with cataract surgery.

Quantifiable outcome

• MINT® 2-year standalone: 97.2% qualified success rate (FDA definition: ≥20% IOP reduction without increasing meds, N=35/36)
• +3 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Two partnerships are on record, tiered flagship and core.

• Bausch + LombflagshipChannel Partner/ Reseller/ Distributor · 25 January 2023Bausch + Lomb invested in Sanoculis during its Series C funding round (January 2023) and entered an exclusive European distribution agreement for Sanoculis' MIMS® glaucoma treatment device. This is a significant strategic partnership providing Sanoculis with broad market access across Europe through a major ophthalmic surgical company. Bausch + Lomb Surgical EMEA is based at 416 Rue Samuel Morse, Le Millenaire 2, BP 1174, 34009 Montpellier, France.
• SkymedcoreChannel Partner/ Reseller/ DistributorSkymed is the Israeli distributor for Sanoculis products including MIMS® and MINT® devices. Located at Hafrat 2, Yavne, Israel 8122702. Contact: 072-2555-240, [email protected]. This distribution partnership enables Sanoculis to reach ophthalmologists and eye surgery centers throughout Israel.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Sight Sciences: Sight Sciences markets the OMNI Surgical System, an ab-interno MIGS device for glaucoma that, like MINT and MIMS, targets interventional glaucoma and combination cataract workflows. Comparable in stage and MIGS focus.
• Glaukos Corporation: Glaukos is the pioneer and market leader in MIGS, with iStent and iStent inject devices used in standalone and combination cataract-MIGS procedures. Directly competes with Sanoculis' MINT and MIMS in the same ophthalmic surgical channels and target surgeon base.
• Nova Eye Medical: Nova Eye Medical sells iTrack, a canaloplasty MIGS device for glaucoma. Targets the same MIGS / interventional glaucoma surgeon base with an ab-interno approach, making it a directly comparable peer.
• New World Medical: New World Medical markets the Kahook Dual Blade, an ab-interno goniotomy device used in standalone and combination cataract-MIGS procedures. Directly competes with Sanoculis in the surgical trabeculostomy space.
• Ellex Medical Lasers (Lumibird Medical): Ellex (now part of Lumibird Medical) offers laser-based MIGS solutions, including laser trabeculoplasty devices. Targets the same MIGS / interventional glaucoma surgeon base as Sanoculis, though with a different mechanism.

Emerging players

• iSTAR Medical: iSTAR Medical develops MINIject, a suprachoroidal MIGS implant. Competes in the same MIGS category with a differentiated mechanism, addressing the same glaucoma patient population and surgeon base as Sanoculis.
• Belkin Vision: Belkin Vision develops the Eagle Direct Selective Laser Trabeculoplasty device, a non-incisional MIGS alternative. Targets the same interventional glaucoma surgeon base with an emerging, non-implant approach.

Regional players

• MicroSurgical Technology: MicroSurgical Technology (MST) manufactures micro-incision surgical instruments used in ophthalmic surgery, including glaucoma procedures. Comparable as a peer in surgical glaucoma instrumentation, with primary presence in the US.

Broad incumbents

• Alcon: Alcon is a global ophthalmic surgical incumbent with the Hydrus Microstent (acquired via Ivantis) and a broad cataract surgery portfolio. Overlaps directly with Sanoculis in MIGS and combination cataract-glaucoma procedures, but competes from a much larger installed base and sales footprint.
• Bausch + Lomb: Bausch + Lomb is both a strategic partner (Series C investor and exclusive European distributor of MIMS) and a broad ophthalmic incumbent with surgical, pharmaceutical, and vision care portfolios. Comparable as a wide-line ophthalmic surgical competitor to Sanoculis' stent-free MIGS offering.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Customer concentration

• LinkedInlinkedin.com/company/sanoculis

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanoculis